Inspire Medical Systems (INSP) officer reports 109-share sale under 10b5-1 plan

Rhea-AI Filing Summary

Inspire Medical Systems insider trading report: Chief Product and Innovation Officer John Rondoni reported selling 109 shares of Inspire Medical Systems common stock on January 9, 2026 at a price of $100 per share. After this sale, he beneficially owns 13,797 shares of the company’s stock.

The filing notes that all sale transactions reported were made under a Rule 10b5-1 trading plan dated May 28, 2025, which is a pre-arranged plan intended to allow executives to sell shares over time. The reported holdings include 140 shares acquired through the company’s 2018 Employee Stock Purchase Plan since a prior Form 4 dated May 21, 2025.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Rondoni John

(Last) (First) (Middle)

C/O INSPIRE MEDICAL SYSTEMS, INC.

5500 WAYZATA BLVD., SUITE 1600

(Street)

GOLDEN VALLEY MN 55416

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Inspire Medical Systems, Inc. [ INSP ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	See Remarks

3. Date of Earliest Transaction (Month/Day/Year)
01/09/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	01/09/2026		S		109	D	$100	13,797(1)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Includes 140 shares acquired under the Issuer's 2018 Employee Stock Purchase Plan since the Reporting Person's Form 4 dated May 21, 2025.

Remarks:

Title: Chief Product and Innovation Officer. All sale transactions reported herein were made pursuant to a Rule 10b5-1 trading plan dated May 28, 2025.

	/s/ Bryan Phillips, Attorney-in-Fact for John Rondoni	01/12/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Inspire Medical Systems (INSP) report for John Rondoni?

Chief Product and Innovation Officer John Rondoni reported a sale of 109 shares of Inspire Medical Systems common stock on January 9, 2026 at $100 per share.

How many Inspire Medical Systems (INSP) shares does John Rondoni own after the reported sale?

After the reported transaction, John Rondoni beneficially owns 13,797 shares of Inspire Medical Systems common stock.

Was the Inspire Medical Systems (INSP) insider sale made under a Rule 10b5-1 trading plan?

Yes. The filing states that all sale transactions reported were made pursuant to a Rule 10b5-1 trading plan dated May 28, 2025, which is a pre-arranged trading arrangement.

What role does John Rondoni have at Inspire Medical Systems (INSP)?

The remarks section identifies John Rondoni as the company’s Chief Product and Innovation Officer.

Are employee stock purchase plan shares included in John Rondoni’s INSP holdings?

Yes. The reported holdings include 140 shares acquired under Inspire Medical Systems’ 2018 Employee Stock Purchase Plan since a prior Form 4 dated May 21, 2025.

Does this Inspire Medical Systems (INSP) insider filing involve derivative securities?

No. The reported transaction involves common stock only, and the derivative securities table shows no derivative transactions.